Biotech Values

[DewDiligence]

Re: EGRX 2Q15 PR/CC notes

The cash balance at 6/30/15 was $103.7M, implying a 2Q15 cash burn of $12.2M:

http://eaglepharm.investorhq.businesswire.com/press-release/eagle-pharmaceuticals-inc-reports-second-quarter-2015-results
http://eaglepharm.investorhq.businesswire.com/press-release/eagle-pharmaceuticals-inc-reports-first-quarter-2015-results

On the 2Q15 CC, the CEO said EGRX will definitely launch the "big bag" generic Treanda product on 5/1/16 (the earliest launch date according to the patent-litigation settlement between the companies) even if the ready-to-use Bendamustine product licensed by TEVA from EGRX is well received in the marketplace. (Previously, the CEO had merely said that EGRX might launch the big-bag product.) The big-bag product is an ordinary generic version of Treanda that is intended to cater to the more price-sensitive portion of the market than the RTU product, which will presumably carry a premium price.

I'm not sure if EGRX's assertion about launching the big-bag product should be taken at face value, or if it's being used as leverage against TEVA to ensure a successful commercialization of the RTU product.

p.s. The PDUFA date for the RTU product is 12/13/15.